Criteria driving therapeutic decisions at baseline | Hizentra N = 117 |
---|---|
Disease-related | |
Type of infectious agent, n (%) | 51 (43.6 %) |
Neutropenia, n (%) | 11 (9.4 %) |
Stage of disease, n (%) | 39 (33.3 %) |
Last gammaglobulin titer, n (%) | 67 (57.3 %) |
Other, n (%) | 21 (17.9 %) |
Treatment-related | |
Ease of administration, n (%) | 80 (68.4 %) |
Volume of injection, n (%) | 76 (65.0 %) |
Other, n (%) | 8 (6.8 %) |
Patient-related | |
Poor venous access, n (%) | 24 (20.5 %) |
Poor tolerance to IVs, n (%) | 9 (7.7 %) |
Difficult hospital access, n (%) | 38 (32.5 %) |
Busy schedule, n (%) | 23 (19.7 %) |
Importance of being independent, n (%) | 71 (60.7 %) |
Associated comorbidities, n (%) | 15 (12.8 %) |
Age, n (%) | 42 (35.9 %) |
Recurrence of infection over the previous 12 months, n (%) | 26 (22.2 %) |
Recurrence of infection over the previous 3 years, n (%) | 24 (20.5 %) |
Satisfactory renal function, n (%) | 13 (11.1 %) |
Other, n (%) | 5 (4.3 %) |
Additional considerations | |
Physician and department experience | 84 (71.8 %) |
Staff decision | 24 (20.5 %) |
Failure of previous prophylactic measures | 20 (17.1 %) |
Other | 7 (6.0 %) |